ReviewNeurogastroenterology and motility2022
Role of the duodenal microbiota in functional dyspepsia.
Review in Neurogastroenterology and motility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07577089 (Multimodal Phenotyping of Functional Dyspepsia), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multimodal Phenotyping of Functional Dyspepsia: Controlled Trial on Response to Cognitive-Behavioral Therapy in Subtypes of Epigastric Pain Syndrome and Postprandial Discomfort Syndrome
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Physical-based therapy for the treatment of functional dyspepsia: a systematic review.Clinical journal of gastroenterology · 2026Pooled it
- Relationship Between Clusters of Multimorbidity and Dementia Risk: A Systematic Review.International journal of geriatric psychiatry · 2025Pooled it
- Sex-Specific Differences in Dyspeptic Symptoms in Children Are Attenuated byPediatric gastroenterology, hepatology & nutrition · 2026Article
- Beyond Malabsorption: The Need for Symptom-Based Assessment in Suspected Lactose Intolerance. Lessons From a Test-Specific Symptom Assessment.Neurogastroenterology and motility · 2026Article
- Lactobacillus Taiwanensis Inhibits Gallstone Formation by Regulating Ileal Metabolism.Current microbiology · 2026Article
- Clinical Evidence Linking the Gut Microbiome and Functional Dyspepsia: A Systematic Review and Meta-Analysis.Biomedicines · 2026Review
- Mechanisms and clinical implications of gut-brain interactions.The Journal of clinical investigation · 2026Review
- Interplay between the gut microbiota and MAPK/NF-κ B/Nrf2 signaling in depression: pharmacological insights from traditional Chinese medicine.Frontiers in pharmacology · 2026Review
- Resveratrol alleviates functional dyspepsia-like pathology by modulating chemokine- and cytokine-related immune-epithelial signaling in the duodenal mucosa.Frontiers in immunology · 2026Article
- Age- and Sex-dependent Effects of High-fructose, High-fat Diets on Small Bowel Inflammation and Hepatic Steatosis in F344 Rats.Journal of neurogastroenterology and motility · 2025Article
- Analysis of gastric mucosa associated microbiota in functional dyspepsia using 16S rRNA gene next-generation sequencing.BMC microbiology · 2025Article
- Current Concepts in Gastroparesis and Gastric Neuromuscular Disorders-Pathophysiology, Diagnosis, and Management.Diagnostics (Basel, Switzerland) · 2025Review
- The Use of Gut Organoids: To Study the Physiology and Disease of the Gut Microbiota.Journal of cellular and molecular medicine · 2025Review
- Network analysis and experimental validation to investigateFrontiers in pharmacology · 2025Article
- Dietary microbes and functional dyspepsia: modulating the gut microecology for therapeutic benefit.Frontiers in nutrition · 2025Review
- Third generation sequencing analysis detects significant differences in duodenal microbiome composition between functional dyspepsia patients and control subjects.Neurogastroenterology and motility · 2025Article
- Menthacarin, a proprietary combination of peppermint and caraway oil, alters cultured human fecal microbiota composition, resulting in increased SCFA production.Frontiers in pharmacology · 2025Article
- Exploring the Mechanism of Shi-San-Wei-He-Zhong-Wan in the Treatment of Functional Dyspepsia Based on Network Pharmacology and Experimental Validation.Combinatorial chemistry & high throughput screening · 2025Article
- [The Relationship of Dysbiosis of Duodenal Microbiome and Functional Dyspepsia].The Korean journal of helicobacter and upper gastrointestinal research · 2024Review
- Analysis of composition of gut microbial community in a rat model of functional dyspepsia treated with Simo Tang.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional dyspepsia (FD) is a common and debilitating gastrointestinal disorder attributed to altered gut-brain interactions. While the etiology of FD remains unknown, emerging research suggests the mechanisms are likely multifactorial and heterogenous among patient subgroups. Small bowel motor disturbances, visceral hypersensitivity, chronic microinflammation, and increased intestinal tract permeability have all been linked to the pathogenesis of FD. Recently, alterations to the gut microbiome have also been implicated to play an important role in the disease. Changes to the duodenal microbiota may either trigger or be a consequence of immune and neuronal disturbances observed in the disease, but the mechanisms of influence of small intestinal flora on gastrointestinal function and symptomatology are unknown. PURPOSE: This review summarizes and synthesizes the literature on the link between the microbiota, low-grade inflammatory changes in the duodenum and FD. This review is not intended to provide a complete overview of FD or the small intestinal microbiota, but instead outline some of the key conceptual advances in understanding the interactions between altered gastrointestinal bacterial communities; dietary factors; host immune activation; and stimulation of the gut-brain axes in patients with FD versus controls. Current and emerging treatment approaches such as dietary interventions and antibiotic or probiotic use that have demonstrated symptom benefits for patients are reviewed, and their role in modulating the host-microbiota is discussed. Finally, suggested opportunities for diagnostic and therapeutic improvements for patients with this condition are presented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.